• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Google backs $27M launch round for Holy Grail R&D work on two tar­gets: a can­cer vac­cine and a uni­ver­sal flu jab

8 years ago
Financing
Startups

Scoop: With its NDA in lim­bo, Iron­shore ex­ecs shut­tered the AD­HD biotech

8 years ago
Pharma

Video: How many PD-1/L1 drugs do we need? Where is im­munother­a­py head­ed? Watch Jay Brad­ner, Hervé Hop­penot, Ellen ...

8 years ago
Special
Pharma

HHS pick Azar draws the line on drug price ne­go­ti­a­tions at Medicare; As­traZeneca inks on­col­o­gy re­search deal at JPM

8 years ago
News Briefing

In a pi­o­neer­ing first, As­traZeneca scores FDA OK to use its PARP against breast can­cer

8 years ago
Pharma

The Cam­bridge siren call: Philips NV mov­ing HQ to mega-project Cam­bridge Cross­ing

8 years ago
Pharma

Why did Abl­ynx board chair­man Pe­ter Fell­ner re­sign in wake of Novo's buy­out of­fer?; Am­gen vet Richard Paul­son tapped ...

8 years ago
Peer Review

Jump­ing on an­ti-ag­ing band­wag­on, Y Com­bi­na­tor joins hunt for the $100B pill

8 years ago
Startups

Head­ed for a block­buster smash, Roche picks up an­oth­er key OK for land­mark MS drug Ocre­vus

8 years ago
Pharma

Genen­tech beefs up its PD-L1 com­bo pipeline, sign­ing the 'don’t eat me' spe­cial­ists at Forty Sev­en

8 years ago
Pharma

Brae­burn bags $110M in launch cash as PDU­FA date rolls up; En­do sub­poe­naed for doc­u­ments on opi­oid painkillers

8 years ago
News Briefing

New study looks at FDA's use of so­cial me­dia to com­mu­ni­cate on drug safe­ty

8 years ago
Pharma

Teva's board slash­es its own com­pen­sa­tion fol­low­ing mas­sive re­struc­tur­ing

8 years ago
R&D

Shire CEO Flem­ming Orn­skov is hatch­ing a few new stretch goals for R&D in 2018 — and be­yond

8 years ago
People

Charles Riv­er buys KWS BioTest for $20M, gain­ing im­munol­o­gy dis­cov­ery ca­pac­i­ty and a UK foot­print

8 years ago
Deals
Outsourcing

Pfiz­er on­col­o­gy head Liz Bar­rett jumps ship to No­var­tis as Bruno St­rig­i­ni steps aside

8 years ago
People

The FDA still hates low T drugs — ex­perts bat back a pair of con­tenders

8 years ago
R&D

Mod­er­na ex­pands pipeline to in­clude liv­er dis­ease pro­grams; Im­pe­r­i­al re­searchers team up with Hep­tares on ...

8 years ago
News Briefing

Truf­fle roots for new biotechs af­ter first close of a planned $240M fund

8 years ago
Financing

Genen­tech adds a new pro­gram for Syn­dax’s lead can­cer drug to its Tecen­triq com­bo plat­form

8 years ago
Pharma

Blue­bird hopes for 3 drug ap­provals by 2019, in­clud­ing CAR-T and gene ther­a­pies

8 years ago
Cell/Gene Tx

GSK’s long-qui­et can­cer R&D group is ready to make some noise as it mounts a break­out late-stage ef­fort

8 years ago
R&D

The End­points 11: A group of dis­rup­tive up­starts on a do-or-die mis­sion to launch new meds

8 years ago
Startups
Special

Glob­al Blood Ther­a­peu­tic­s' sick­le cell dis­ease drug gets break­through ther­a­py sta­tus; Boehringer In­gel­heim will ...

8 years ago
News Briefing
First page Previous page 1057105810591060106110621063 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.